MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
593.31
-2.35
-0.39%
After Hours: 593.31 0 0.00% 17:59 11/12 EST
OPEN
597.50
PREV CLOSE
595.66
HIGH
598.38
LOW
586.56
VOLUME
338.71K
TURNOVER
--
52 WEEK HIGH
614.23
52 WEEK LOW
445.81
MARKET CAP
25.27B
P/E (TTM)
22.38
1D
5D
1M
3M
1Y
5Y
1D
What United Therapeutics Holders Bought Into
Simply Wall St · 23h ago
Liquidia extends gains as Raymond James upgrades on Yutrepia launch
Seeking Alpha · 1d ago
Nvidia downgraded, Mercury Systems upgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Liquidia price target raised to $66 from $58 at Needham
TipRanks · 2d ago
Liquidia price target raised to $87 from $70 at BTIG
TipRanks · 2d ago
United Therapeutics (UTHR) Stock Still Looks Like A Bargain As Its 184% Run Continues
Simply Wall St · 2d ago
DraftKings downgraded, AMD upgraded: Wall Street’s top analyst calls
TipRanks · 3d ago
United Therapeutics Price Target Announced at $660.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
More
About UTHR
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.

Webull offers United Therapeutics Corp stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.